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ABSTRACT 
Aim: Selection bias could be an important limiting factor in psychiatric neurobiological research. 
The study aim was to compare, within an early psychosis program, patients who agreed to 
participate to neurobiological research with patients who refused.  
Methods: 284 patients with early psychosis were assessed at baseline on a large set of socio-
demographic and clinical variables and were followed-up over 36 months.  
Results: There were no differences between groups, except regarding forensic/psychiatric 
history, lifetime substance abuse and social-occupational level during follow-up.  
Conclusions: While patients participating to neurobiological research seem representative of 
our clinical cohort, the few differences identified may deserve attention.  
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1. INTRODUCTION 
Exciting or demanding biomedical investigations may attract a specific subgroup of volunteers 
and conclusions derived from such research may present serious limitations (Gustavsson et al., 
1997). Referral questions, motivation and ability to consent may induce selection bias of 
patients consenting to participate in psychiatric neurobiological research. Moreover many of 
such studies are based on relatively small number of participants. This might contribute to the 
lack of consensus between studies and affect findings’ generalisation. Selection bias may thus 
fuel the so-called “replicability crisis” (Barch and Yarkoni, 2013; Gorgolewski and Poldrack, 
2016; Tackett et al., 2016).  
A study investigating the willingness to take part in research consecutively to psychiatric 
admission reported high (>70%) readiness to participate, and found that rather than 
remuneration or other factors, altruistic motivations such as the wish to help science to progress 
and to allow patients to benefit from better treatments were the most frequent (Zullino et al., 
2003). Selection bias is difficult to investigate because data on patients who did not participate 
are typically not available. Data stemming from prospective clinical cohort studies can offer a 
context where such a limitation may be overcome. The goal of our study was to compare the 
characteristics, within a clinical cohort of patients with early psychosis treated at the Treatment 
and early Intervention in Psychosis Program (TIPP), of patients who consented to 
neurobiological research with those who didn’t.  
 
2. METHODS 
2.1 Participants 
TIPP is a specialized early psychosis program at the Department of Psychiatry in Lausanne 
University Hospital, Switzerland. Inclusion criteria are age between 18-35, living in catchment 
area (population about 300’000) and meeting criteria for psychosis, as defined by the ‘psychosis 
threshold’ subscale of the Comprehensive Assessment of At Risk Mental States scale (Yung et 
al., 2005). The program has been detailed elsewhere (Baumann et al., 2013). Patients with 
psychosis related to intoxication/organic brain disease, IQ<70 or that have been taking 
antipsychotic medication for more than six months are referred to other programs. All patients 
treated at TIPP are fully assessed at baseline on numerous premorbid characteristics and are 
then assessed regularly in order to monitor outcome and adapt treatment if improvement is 
insufficient. Access to the clinical data was granted by the Ethics Committee of Lausanne 
University and consequently all patients who received treatment within this program were 
automatically included in this study. This allowed us to have data on all patients whether or not 
they participated to neurobiological studies, which was based on an informed consent 
procedure. As such, and considering we are the only specialised program in our catchment 
area, this sample is highly representative of patients with early psychosis in our region. 
 
2.2 Clinical assessments  
Detailed evaluation of past medical history, demographic characteristics, exposure to adverse 
life events as well as symptoms and functioning was performed by case managers (CM) and a 
psychologist through interviews and a structured questionnaire. At baseline and after 2, 6, 12, 
18, 24, 30 and 36 months of treatment, a series of assessments focusing on symptoms and 
functional level were conducted.  
Functional characteristics at baseline were assessed with the Modified Vocational Status Index 
and Modified Location Code Index Independent living (MVSI & MLCI; Tohen et al., 2000). 
Premorbid functional level was evaluated with the Premorbid Adjustment Scale (PAS; Cannon-
Spoor et al., 1982). Academic, social, childhood and early-adolescence sub-scores were 
computed (MacBeth and Gumley, 2008). Past history of trauma (sexual or physical abuse 
before age 16) was evaluated by CM over the entire program (Alameda et al., 2016). Past 
diagnosis of substance abuse/dependence was rated according to DSM-IV. The Global 
Assessment of Functioning (GAF) and Social and Occupational Functioning Assessment Scale 
(SOFAS; American Psychiatric Association, 1994) were used to assess the functional level at 
baseline. While GAF includes the intensity of symptoms, SOFAS only focus on social and 
occupational level. The lowest SOFAS and GAF scores before presentation were also 
estimated. Insight into illness was evaluated as complete, partial or absent (Conus et al., 2007). 
Severity of illness at baseline was assessed with the Clinical global impression scale (CGI; Guy, 
1976).  
Psychopathology and functional level were scored at each assessment, with SOFAS, GAF, the 
Positive and Negative Syndrome Scale (PANSS; Kay et al., 1987) and the Montgomery-Asberg 
Depression Rating Scale (MADRS; Montgomery and Asberg, 1979).  
This study is based on the prospective follow-up of the first 284 patients who were treated within 
TIPP. 
 
2.3 Participants consenting to a biomarker study 
In the frame of a discussion with the CM in charge of the patient, a biomarker study was 
proposed to each patient during the first months following their entry in TIPP. The delay for 
presenting the study was justified by the wish to prioritize clinical intervention and treatment 
during the acute phase of psychosis when patients typically present inability to provide informed 
consent. The biological assessments are part of a project focusing on the identification of 
neurobiological markers in the early phase of psychosis (hereafter, biomarker study; e.g. 
Fournier et al., 2014). Beyond psychopathology, these assessments include neuropsychological 
tests, genetic, biochemical and metabolomics analysis of blood and skin derived fibroblasts, 
multimodal magnetic resonance imaging (structural MRI, fMRI and diffusion spectrum imaging, 
magnetic resonance spectroscopy) and EEG. Patients included in the biomarker study provided 
fully informed consent, and all procedures were approved by the Local Ethics Committee. 
Patients could also agree to participate to only a subset of tests of the full battery. As 
acknowledgment a symbolic financial compensation (from 30 to a maximum of 130 CHF for 
each visit depending on the number of tests) was proposed. 
 
2.4 Statistical analysis 
Comparisons between groups were performed with independent t-tests for continuous variables 
and Pearson's Chi-Square tests (or Fisher Exact tests) for categorical variables. Because of the 
longitudinal nature of some of the data, models were estimated in the multilevel framework. 
Mixed effects models repeated measures analysis of variance (MMRM) was used to determine 
group differences over time for the different measures. Time was introduced as a “within-group” 
factor and participation as a “between-groups” factor. From the model, the main effects for 
participation and time can be examined as well as their interaction. The selection of the optimal 
within subject covariance matrix in each MMRM model was determined with the AIC coefficient. 
Unstructured, autoregressive, compound symmetric and Toeplitz structures were tested. 
Because the homogeneity of variances across occasions may not hold, we also included 
heterogeneous versions of these structures. 
 
3. RESULTS 
Out of 284 patients, 95 (33.45%) consented to the biomarker study and 189 (66.55%) didn’t.  
3.1 Sociodemographic and clinical data  
Participants who were included in the biomarkers study differed from other patients on a small 
number of variables (Table 1): they had lower rate of history of offences (p=.043, OR=0.41) but 
higher rate of past psychiatric treatment (p=.009, OR =2.02). Patients who consented to the 
biomarker study were more likely to have a lifetime history of cannabis addiction (p=.012, 
OR=1.98) and other substances addiction (p=.006, OR=3.65) as well as lifetime history of other 
substances abuse (p=.005, OR=2.61). 
 
3.2 Clinical and functional outcomes during the follow up  
Results of the longitudinal analyses revealed that the groups did not differ regarding positive 
symptomatology (F1,224.340=0.742, p=.390, mean difference = 0.43), negative symptomatology 
(F1,194.718=0.088, p=.766, mean difference = -0.19) or depressive symptomatology 
(F1,221.764=0.801, p=.372, mean difference = -0.86) during the follow-up. Similarly, for general 
functioning assessed with the GAF, no overall differences could be highlighted (F1,273.444=3.281, 
p=.071, mean difference = -2.79). Patients included in the biomarkers study scored on average 
2.96 points lower than other patients when general functioning was assessed by the SOFAS 
(F1,276.888=3.894, p=.049). Post-hoc pairwise comparison of various assessment time points 
revealed no differences for the first half of the follow-up (baseline: p=.317, 2 months: p=.988, 6 
months: p=.292, 12 months: p=.074) and also after 30 months (p=.464). Assessments during 
the second part of the follow-up (18 months: p=.027, mean difference = -4.48; 24 months: 
p=.006, mean difference = -5.68; 36 months: p=.041, mean difference = -4.39) revealed higher 
SOFAS scores in patients included in the biomarker study, contributing to the overall group 
difference (Figure 1). Comparison of the rate of improvement between baseline and all 
endpoints revealed no significant differences. 
 
4. DISCUSSION 
Globally, our results suggest that, in our cohort, patients included in a biomarker study were 
globally representative of all patients treated in our program and that our results can reasonably 
be generalized to other patients with early psychosis. While this need to be replicated in other 
samples, this observation is important when considering the important role translational 
research may play in advancing our understanding of the basic mechanisms linked to severe 
mental disorders. However, the few differences identified may deserve attention and should be 
systematically evaluated in future studies. 
The relatively high rate of consent to the biomarker study (close to 35%) is probably linked to 
the role played by case managers who establish a trusting relationship with patients, 
considering that, according to Zullino et al. (2003), patients rely greatly on their treating team to 
make a decision in this regard. 
 
While baseline and premorbid characteristics were similar in both groups, they differed in two 
domains. First, patients who refused the biomarker study were more likely to have had a history 
of offences. This is in line with Keks et al. (1991) who reported that patients refusing a neuro-
endocrine study were more likely to display hostility. It is likely that young patients who had to 
deal with the judiciary system would be less trusting of any form of institution and hence less 
likely to trust clinicians and researchers. This is in line with the observation that patients with 
early psychosis who have a forensic history are more likely to disengage from treatment (Conus 
et al., 2010). Second, patients who consented to the biomarker study were more likely to have a 
lifetime history and/or current substance abuse comorbidity. This finding raises the ethical issue 
of the role played by the financial compensation that we provided and the possibility it 
contributed to the perpetuation of substance abuse and this needs to be further explored. 
However, the observation by Zullino et al. (2003) that financial compensation was rarely 
mentioned by patients as an argument neither to agree (23%) nor to refuse (7%) participation to 
research may temper this concern. Considering the impact of cannabis and other substances on 
neuro-biological processes (for example see Rigucci et al., 2017) as well as the impact of 
substance abuse discontinuation on outcome (Lambert et al., 2005; Schoeler et al., 2016) , it is 
very important to assess this variable in such studies.  
The analysis of clinical data revealed there were no differences between groups regarding 
symptoms and GAF scores at baseline and during the study, showing that patients who 
consented to the biomarker research were not less ill than those who refused. Although the 
difference we observed on the SOFAS rating during the second half of the treatment phase was 
statistically significant, its effect size was negligible, and rate of change between both groups 
were not different.  
 
Conclusion 
Our study showed that, although it implied an important number of assessments, patients of our 
cohort who participated to our biomarker study were globally representative of patients in the 
entire cohort. While this needs to be replicated in other samples and the few differences 
identified should be systematically evaluated in future studies, this suggests that findings from 
neurobiological studies are likely to have a good validity and can be generalised to other 
patients with early psychosis.   
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Figure caption. 
 
Figure 1. Social and Occupational Functioning Assessment Scale (SOFAS) scores over 
36 months. * = p<.05. Overall group difference across all measurements: F1,276.888 = 3.894, p = 
.049. No significant differences between groups in the rate of improvement between baseline 
and all endpoints. 
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Table 1. Sociodemographic and clinical data according to inclusion in neuroscience studies. 
 Total 
N = 284 
Not included 
N = 189 
Included  
N = 95 
statistic p-value Effect size 
Gender, male, % (N) 64.4 (183) 60.8 (115) 71.6 (68) 2(1) = 3.178 .075 OR = 1.63 
 
Age in year, M (SD) 
 
 
24.65 (4.77) 
 
24.83 (4.89) 
 
24.31 (4.54) 
 
t(282) = 0.866 
 
.387 
 
d = -0.11 
 
Duration of untreated psychosis 
in days, Mdn (IQR)a 
 
90.5 (474.0) 
 
89.0 (437.0) 
 
98.0 (489.0) 
 
U = 8758.5 
 
.737 
 
Z = -0.34 
 
Socio-economical level, % (N) 
Low 
Intermediate 
High 
 
 
19.0 (54) 
44.7 (127) 
36.3 (103) 
 
 
22.8 (43) 
43.4 (82) 
33.9 (64) 
 
 
11.6 (11) 
47.4 (45) 
41.1 (39) 
 
 
2(2) = 5.276 
 
 
.072 
 
 
 = 0.14 
 
Education in year, M (SD) 
 
9.80 (2.74) 
 
9.66 (2.91) 
 
10.04 (2.42) 
 
t(247) = -1.077 
 
.283 
 
d = 0.14 
 
Marital status, % (N) 
Single 
Maried 
Divorced 
Cohabitation 
 
 
83.1 (231) 
9.4 (26) 
2.9 (8) 
4.7 (13) 
 
 
81.5 (150) 
11.4 (21) 
25.7 (5) 
4.3 (8) 
 
 
86.2 (81) 
5.3 (5) 
3.2 (3) 
5.3 (5) 
 
 
F.E.T 
 
 
.399 
 
 
 = 0.10 
 
Born in Switzerland, % (N) 
 
53.5 (152) 
 
51.3 (97) 
 
57.9 (55) 
 
2(1) = 1.098 
 
.295 
 
OR = 1.31 
 
Professional activity, % (N) 
Full time job 
Student/Traineeship 
Part time job 
Disability annuity 
On Sickness leave 
Unemployed 
 
 
12.2 (34) 
16.5 (46) 
2.5 (7) 
3.2 (9) 
17.6 (49) 
47.8 (133) 
 
 
12.4 (23) 
15.7 (29) 
2.7 (5) 
3.8 (7) 
17.3 (32) 
48.1 (89) 
 
 
11.8 (11) 
18.3 (17) 
2.2 (2) 
2.2 (2) 
18.3 (17) 
47.3 (44) 
 
 
F.E.T 
 
 
.983 
 
 
 = 0.06 
 
Lifestyle, % (N) 
Family  
Independent household 
With friends 
Pension / care home 
Unsettled (hotel, shelter 
homeless) 
 
 
40.1 (110) 
26.6 (73) 
23.4 (64) 
3.6 (10) 
6.2 (17) 
 
 
37.2 (68) 
26.8 (49) 
25.7 (47) 
3.3 (6) 
7.1 (13) 
 
 
46.2 (42) 
26.4 (24) 
18.7 (17) 
4.4 (4) 
4.4 (4) 
 
 
F.E.T 
 
 
.496 
 
 
 = 0.11 
 
Premorbid Adj. (PAS) M (SD) 
Childhood 
Early adolescence 
Social 
Academic 
Total 
 
 
0.30 (0.19) 
0.32 (0.17) 
0.28 (0.20) 
0.35 (0.20) 
0.31 (0.17) 
 
 
0.30 (0.19) 
0.32 (0.18) 
0.29 (0.21) 
0.35 (0.21) 
0.30 (0.17) 
 
 
0.31 (0.18) 
0.31 (0.16) 
0.28 (0.19) 
0.36 (0.19) 
0.32 (0.16) 
 
 
t(216) = -0.568 
t(220) = 0.223 
t(214) = 0.206 
t(219) = -0.436 
t(198) = -0.468 
 
 
.571 
.824 
.837 
.664 
.641 
 
 
d = 0.05 
d = -0.06 
d = -0.05 
d = 0.05 
d = 0.12 
 
Past suicide attempt, % (N) 
 
13.5 (36) 
 
11.5 (20) 
 
17.2 (16) 
 
2(1) = 1.694 
 
.193 
 
OR = 1.60 
 
History of traumab, % (N) 
 
28.8 (81) 
 
29.0 (54) 
 
28.4 (27) 
 
2(1) = 0.011 
 
.915 
 
OR = 0.97 
 
Forensic history, % (N) 
 
14.3 (35) 
 
17.6 (28) 
 
8.1 (7) 
 
2(1) = 4.088 
 
.043 
 
OR = 0.41 
 
Offences during program, % (N) 
 
11.9 (16) 
 
13.3 (11) 
 
9.8 (5) 
 
2(1) = 0.357 
 
.550 
 
OR = 0.71 
 
Psychiatric history, % (N) 
 
61.0 (169) 
 
55.5 (101) 
 
71.6 (68) 
 
2(1) = 6.789 
 
.009 
 
OR = 2.02 
 
Familial psychiatric history, % 
(N) 
 
62.1 (159) 
 
61.6 (101) 
 
63.0 (58) 
 
2(1) = 0.053 
 
.818 
 
OR = 1.06 
 
Familial schizophrenia history, % 
(N) 
 
22.8 (49) 
 
22.4 (30) 
 
23.5 (19) 
 
2(1) = 0.033 
 
.856 
 
OR = 1.06 
 
Lifetime substance abuse 
(DSM), % (N) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alcohol 
Cannabis 
Other substances 
25.2 (68) 
38.5 (104) 
14.0 (39) 
22.7 (41) 
35.2 (63) 
9.8 (18) 
30.3 (27) 
45.1 (41) 
22.1 (21) 
2(1) = 1.870 
2(1) = 2.476 
2(1) = 7.805 
.171 
.116 
.005 
OR = 1.48 
OR = 1.51 
OR = 2.61 
Lifetime substance addiction 
(DSM), % (N) 
Alcohol 
Cannabis 
Other substances 
 
 
8.9 (24) 
30.7 (83) 
6.8 (19) 
 
 
7.2 (13) 
25.7 (46) 
3.8 (7) 
 
 
12.2 (11) 
40.7 (37) 
12.6 (12) 
 
 
2(1) = 1.892 
2(1) = 6.343 
2(1) = 7.617 
 
 
.169 
.012 
.006 
 
 
OR = 1.79 
OR = 1.98 
OR = 3.65 
 
Insight at presentation, % (N) 
Absent 
Partial 
Complete 
 
 
35.6 (96) 
47.0 (127) 
17.4 (47) 
 
 
35.9 (65) 
50.3 (91) 
13.8 (25) 
 
 
34.8 (31) 
40.4 (36) 
24.7 (22) 
 
 
U = 7416.5 
 
 
.250 
 
 
 = 0.14 
 
GAF, M (SD) 
Baseline 
Worst during psychosis 
 
 
37.91 
(16.23) 
26.08 
(10.90) 
 
 
37.24 
(16.66) 
25.45 
(11.23) 
 
 
39.17 (15.41) 
27.16 (10.30) 
 
 
t(257) = -0.908 
t(248) = -1.204 
 
 
.365 
.230 
 
 
d = 0.12 
d = 0.16 
 
SOFAS, M (SD) 
Baseline 
Worst during psychosis 
 
 
39.80 
(15.35) 
29.10 
(11.77) 
 
 
39.19 
(15.83) 
28.51 
(12.08) 
 
 
40.98 (14.41) 
30.14 (11.20) 
 
 
t(267) = -0.908 
t(251) = -1.061 
 
 
.365 
.290 
 
 
d = 0.12 
d = 0.14 
 
CGI, M (SD) 
Baseline 
Higher during psychosis 
 
 
4.81 (1.38) 
5.81 (0.76) 
 
 
4.86 (1.39) 
5.83 (0.80) 
 
 
4.72 (1.36) 
5.78 (0.70) 
 
 
t(240) = 0.764 
t(240) = 0.460 
 
 
.445 
.646 
 
 
d = -0.10 
d = -0.07 
 
Diagnostic, % (N) 
Schizophrenia 
Schizophreniform/brief 
Schizo-affective 
Major depressionc 
Bipolar disorder 
Other  
 
 
59.5 (169) 
11.6 (33) 
9.5 (27) 
3.5 (10) 
7.4 (21) 
8.5 (24) 
 
 
57.1 (108) 
13.8 (26) 
7.9 (15) 
4.8 (9) 
6.9 (13) 
9.5 (18) 
 
 
64.2 (61) 
7.4 (7) 
12.6 (12) 
1.1 (1) 
8.4 (8) 
6.3(6) 
 
 
F.E.T 
 
 
.184 
 
 
 = 0.16 
Note. Analyses between groups were performed with t-tests for continuous variables and Chi-Square test (or Fisher’s 
exact test when appropriate) for categorical variables. Mdn = Median. IQR = Interquartile range. F.E.T. = Fisher’s 
exact test. a = Because DUP values were highly skewed comparisons were performed using Mann-Whitney U tests; b 
physical or sexual abuse c with psychotic features. OR = odd ratio. 
 
 
